Launch medtech.
Lead the market.
Specialized teams advancing diagnostics from idea to impact.
Trusted experts in technology launch and commercialization.
TigerTeam aims to identify, acquire, and advance innovative diagnostics and devices with the potential to disrupt healthcare. With our deep expertise and proven track record of successful company creation, scaling, and exit, we will partner with innovators to bring the best new products to patients.
TigerTeam Bio Expertise
Molecular diagnostics mastery
Accelerating innovation with deep technical expertise in diagnostics and medtech.
Full-spectrum commercialization
Guiding technologies from concept to compliant, rapid market launch.
Powerful industry alliances
Connecting innovators and investors with key partners to drive adoption.
Operational excellence delivered
Leaders managing complex projects with precision and accountability.
Team
Tara Maddala, Ph.D.
Biostatistics and Clinical Development Consultant
Biostatistics; Clinical Trial Design & Analysis; Analytical and Clinical Validation; Clinical Development Strategy; Scientific Advisory Board
Julie Ballard
Clinical Laboratory Consultant
Clinical Laboratory Operations; Quality Systems; CLIA Regulatory Compliance, LDT Development and Validation
Ayse Tezcan, MPH, Ph.D.
Clinical Operations Consultant
Clinical Study Operations; Real-World Evidence; Patient Registries; Data Quality
Cheryl Chin, MBA
Diagnostics Commercial Strategy Consultant
Portfolio Prioritization; Product Strategy/Roadmap; Product Requirements; Go-to-Market Strategy; Market Research/KOL engagement
David Lo, MBA
Corporate and Business Development Consultant
Strategic Partnerships; Licensing; M&A; Capital Strategy and Fund Raising; Market Expansion and Commercial Partnerships;
Haluk Tezcan, MD
Oncologist and Clinical Development Consultant
Practicing Oncologist and Hematologist; Clinical Development; Clinical Trial Programs; Principal Investigator; Translational Medicine; Scientific Advisory Board
Harit Nandani, MS
Clinical Data and Software Strategy Consultant
Clinical Data Management & Analytics; Software and Data Engineering; Modern AI Tools
Ilma Abbas
Clinical Data Management Consultant
Clinical Data Management; Database Build; Clinical Trial Operations & Oversight; Data Analysis
Jaclyn Manthe
Operations and Executive Support
Executive Support; Operations and Project Management; Vendor Coordination; Client Relations; Operational Excellence
Jennifer Geis, Ph.D.
Biomarker and Biostatistics Consultant
Biomarker Discovery; Classifier Building; Algorithm Development; Analytical Validation; Clinical Study and LDT Support
Jerome Braun, Ph.D.
Biostatistics and Statistical Methods Consultant
Statistical Design, Statistical Programming, Statistical Analysis, Bayesian Analysis
Kim Langone, Ph.D.
R&D Scientific Consultant
Biomarker Discovery; Assay Development; Product Development; Analytical Validation; Tech Transfer; Systems Integration
Maggie Louie, Ph.D.
Translational Research Consultant
Translational Research; External Partnerships; Competitive Intelligence and Technology Evaluation
Marra Francis, MD
Clinical Development/Med Affairs Consultant
Clinical Development & Strategy; Product Development; Women’s Health; Oncology; Medical Affairs; Scientific Advisory Board
Meredith Halks-Miller, MD
Pathology and Diagnostic Development Consultant
Pathology; CLIA Lab Leadership; Diagnostic Development; Analytic Validation
Mike Konwiak
Project Management and Operations Consultant
Order-to-Result Strategy and Enablement; Cross-Functional Program Delivery; Product Roadmapping and Requirements
Shanna Allen
Clinical Operations Consultant
Clinical Operations; Clinical Trial Management; Project Management; CRO Set-up and Oversight; Vendor Set-up Management; Sample Management
Shirley Vu
Clinical Data Management Consultant
Clinical Data Management; EDC Configuration and Implementation; R-based Data Analysis and Reporting
Tony Wu
Clinical Data Engineering/AI Enablement Consultant
Data Engineering; Software Development; Clinical Data Science; Statistical Programming; AI Enablement; Clinical and Laboratory Software
BIO
Dr. Tara Maddala, PhD, is co‑founder and managing partner of TigerTeam Bio and has over 25 years of experience bringing therapeutics, diagnostics, and devices from concept to commercialization. She is an expert statistician in clinical and product development strategy for diagnostic and device companies. Dr. Maddala has led quantitative and clinical development teams at Delfi Diagnostics and GRAIL, overseeing some of the largest studies in genomic medicine and multiple pivotal and regulatory programs. Previously, she led biostatistics at Genomic Health and Clinimetrics, contributing to Oncotype DX development and therapeutic filings. She is co‑inventor on several cancer genomic patents and has authored numerous peer‑reviewed publications and congress presentations. Dr. Maddala is known for bringing structure and clarity to complex development questions, helping teams choose the right evidence strategy rather than the most convenient one.
Clinimetrics CRO; DELFI Diagnostics; Genomic Health; GRAIL; UCSF
BIO
Julie Ballard is co‑founder and managing partner of TigerTeam Bio and a licensed Clinical Laboratory Scientist with more than 25 years of experience building and leading CLIA‑certified laboratories. She played foundational roles at Genomic Health, Guardant Health, and GRAIL, where she established quality systems, regulatory compliance programs, and lab operations. Julie has deep expertise in LDT development and validation of oncology and molecular diagnostics and has guided multiple labs through CLIA, CAP, and CLEP approvals. She has repeatedly taken laboratories from concept to full operational readiness, building teams and systems that support high‑complexity testing at scale.
Genomic Health; Guardant Health; GRAIL; Seer; Stanford Hospital; ViroLogic
BIO
Ilma Abbas is a Clinical Data Management professional with expertise in end‑to‑end clinical trial data oversight, regulatory compliance, and database lifecycle management. She ensures data integrity from study startup through database lock and archival and works closely with Clinical Operations, Medical, and Biostatistics teams to streamline processes and maintain GCP‑compliant standards. Ilma designs structured data workflows that uncover issues early, shorten database lock timelines, and reduce downstream rework, efficiently executing projects from electronic database configuration through database lock.
BIO
Shanna Allen is a clinical research professional with 20+ years of experience leading end‑to‑end execution of drug, device, and diagnostic trials across all phases. She has built her expertise in top CRO, pharmaceutical, and diagnostic organizations, with recent focus on IVD and LDT development for emerging start‑ups. Her work spans trial planning, site start‑up, monitoring and oversight, vendor strategy, SOP and protocol development, specimen handling, and close partnership with Data Management on eCRF design and UAT. Shanna is frequently engaged to lead complex, multi‑center programs on aggressive timelines while maintaining quality and inspection readiness.
Aqtual; DELFI Diagnostics; Exact Sciences; Everest Detection; IQVIA; Parexel; Rho, Inc.
BIO
Dr. Jerome Braun, PhD, is an independent statistical consultant with 25+ years of experience across the pharmaceutical, biotechnology, and medical device industries, as well as other scientific and engineering fields. A classically trained statistician, he is also fluent in Bayesian methods, statistical programming, messy data handling, and machine learning. He has worked with academia, industry, and government on grant‑funded research, development programs, manufacturing, and legal and regulatory matters. Dr. Braun is often brought in for unconventional or complex data problems and is known for translating advanced statistical concepts into clear, defensible recommendations for multidisciplinary teams.
BIO
Cheryl Chin has over 20 years of experience leading market development and commercialization in molecular diagnostics and life sciences. She develops product strategies at the intersection of scientific innovation, clinical need, and market opportunity, informing product requirements, evidence plans, and long‑term strategic roadmaps. Most recently Vice President of Marketing at Exai Bio, she previously held leadership roles at Myriad Genetics, Crescendo Bioscience, and Johnson & Johnson across oncology, autoimmune, and dermatology. Cheryl has launched and scaled multiple diagnostic products and is known for clarifying where a product truly fits in the care pathway and how to accelerate product adoption
Crescendo Bioscience, Exai Bio, Johnson & Johnson, Myriad Genetics
BIO
Dr. Marra S. Francis, MD, is a board‑certified obstetrician‑gynecologist and biotech executive with more than 20 years of experience in diagnostic and life science product development. She has served as Chief Medical Officer and medical affairs leader for multiple early‑ and growth‑stage companies, leading clinical strategy, target product profile development, regulatory planning, and market positioning. Dr. Francis provides strategic oversight of clinical study workflows to drive seamless operational and logistical alignment and cultivates key opinion leader networks that support evidence generation, guideline inclusion, and payer coverage. She is particularly focused on aligning clinical value with commercial strategy to accelerate adoption while managing development risk.
Droplet Biosciences; EverlyWell; Myriad Genetics; PinkDx; Sema4
BIO
Dr. Jennifer Geis, PhD, is a research statistician with over 12 years of experience in genomic signal detection, high‑dimensional data analysis, and machine learning for biomedical and clinical research. She specializes in biomarker discovery, classifier development, error modeling, and robust and non‑parametric methods. Dr. Geis has extensive experience in CLIA‑regulated environments, supporting experimental design, clinical study design, and analytical validation for LDTs. She is currently the VP of Data Science at InterVenn, where she leads initiatives in AI algorithm development, bioinformatics, and classifier modeling for research and LDTs.
BIO
Dr. Meredith Halks‑Miller, MD, is a board‑certified Anatomic and Neuropathologist with over 40 years of experience in academic and commercial settings. In 2013, as Medical Laboratory Director at Verinata Health (now Illumina), she made the seminal discovery that cfDNA in the blood of pregnant women could indicate maternal malignancies, work that led to the establishment of GRAIL and inspired numerous companies in early cancer detection. She has broad expertise in CLIA lab leadership, analytic validation, clinical and biomolecular data evaluation, and diagnostic product development. Dr. Halks‑Miller trained at UCSF and Stanford and held faculty positions at both institutions; she is now retired but available for select consultations.
Berlex Biosciences; GRAIL; Illumina/Verinata Health; Pathwork Dx; Stanford; UCSF
BIO
Mike Konwiak has 20 years of healthcare experience, including 12 years in cancer diagnostics leading order-to-result delivery across early-stage startups and scaling public companies. He has directed complex, cross-functional programs spanning product, engineering, laboratory, and commercial teams. At DELFI Diagnostics, he led order-to-result infrastructure that achieved >99% order accuracy at launch and drove pilot readiness and Epic-native patient identification tools. Previously at Exact Sciences and Genomic Health, Mike launched Salesforce order-to-result platforms and led product owners for provider portals, test reports, and integrations. He thrives in early-stage settings where speed, ambiguity, and cross-functional alignment are daily constants.
CSC Consulting; DELFI Diagnostics; Exact Sciences; Genomic Health; HighPoint Solutions
BIO
Dr. Kim Langone, PhD, is an R&D executive with 25 years of experience advancing molecular diagnostics. She has led multiple assays from concept through validation and commercialization, including several of Genomic Health’s Oncotype DX tests and liquid biopsy assays in oncology and transplantation. Dr. Langone has broad technical experience and a strong track record of transitioning assays from research to robust diagnostic tools. She currently serves as SVP R&D at Fellow Health Inc., where she explores seminal fluid as a novel liquid biopsy specimen type and leads teams that balance scientific ambition with operational robustness.
BIO
David Lo is a corporate and business development executive with experience across molecular diagnostics, biopharma, healthcare investment banking, and management consulting. He has led licensing, strategic partnerships, capital formation, and growth initiatives that scale platforms and expand product portfolios. David has structured and executed complex transactions, including pharma collaborations, diagnostic partnerships, and strategic financings, integrating scientific, commercial, and financial perspectives. Earlier in his career, he advised healthcare companies and investors on M&A, capital raising, and strategic positioning. He is focused on advancing precision medicine and diagnostic platforms through partnerships that create durable enterprise value.
CareDx; Chiron; Counsyl; Freenome; MAP Pharma; ThinkEquity Partners; Wilson Sonsini
BIO
Dr. Maggie Louie, PhD, is a scientific leader in oncology and translational research with expertise at the intersection of computational biology, technology, and human disease. She partners with start‑ups and venture‑backed companies to design integrated preclinical and translational strategies that turn platform data into actionable biomarker and patient stratification frameworks. Her work helps teams move from complex multi‑omics outputs to clear translational hypotheses, decision points, and collaborations. Dr. Louie is particularly focused on building productive partnerships with biopharma and academia that advance programs and generate high‑quality science.
BIO
Jaclyn Manthe is a Virtual Operations Administrative Executive with extensive experience supporting leaders, managing business operations, and optimizing administrative systems in remote environments. She excels in calendar and inbox management, project coordination, process improvement, and cross‑functional communication, enabling executives to focus on strategic work. Jaclyn has supported leadership teams through high‑growth phases, re‑organizations, and product launches, ensuring operational details do not impede progress. Leaders rely on her as a trusted partner who anticipates needs, protects focus time, and keeps distributed teams aligned.
Blue Tiger Leadership; ConverseNet; Delve Consulting; Equalus; InsightRX; Previse
BIO
Harit Nandani is a clinical trials data analytics and software professional with 15 years of experience across big pharma, cancer diagnostics, and health tech. He currently consults for small to mid‑sized biotech, diagnostics, and health tech companies as a fractional head of clinical data. Previously, as Director of Clinical Data at GRAIL, he led data and systems implementation for the NHS‑Galleri cancer diagnostics trial, co‑authored two patents in natural language processing, and built partnerships with the NHS, Mayo Clinic, and Cleveland Clinic. Before that, he served as a team lead at Gilead Sciences, driving pivotal Phase 3 FDA submissions in oncology. Harit is passionate about harnessing modern tools to get drugs and diagnostics to patients faster and rethinking what the clinical trial data value chain can look like.
BIO
Dr. Ayse Tezcan, PhD, is a healthcare executive with over 25 years of experience in clinical development, clinical operations, real‑world evidence, and data quality. She has held leadership roles at Lexent Bio, Foundation Medicine (Roche), and N‑Power Medicine and built a community‑based oncology research program that exceeded national enrollment and retention benchmarks. Dr. Tezcan has led multi‑site registries and observational studies and established teams that capture trial‑grade data in routine care. She co‑founded the Ca.Re. Foundation to expand access to cancer trials in rural communities and, as co‑founder of Athea Oncology, advises early‑stage diagnostic companies on clinical development, operations, and market entry.
Athea Oncology; Ca.Re. Foundation, FMI (Roche); LexentBio; N-Power Medicine
BIO
Dr. Haluk Tezcan, MD, is Chief Medical Officer at Droplet Biosciences and Co‑principal at Athea Oncology, with over 30 years of experience in oncology, hematology, clinical research, and executive leadership. A board‑certified medical oncologist and hematologist, he has focused his career on advancing cancer diagnostics and personalized medicine. Dr. Tezcan previously served as VP of Clinical Development at Foundation Medicine and as CMO at Lexent Bio, where he led development of a liquid biopsy platform acquired by Roche/Foundation Medicine, and he has held senior roles at N‑Power Medicine, Counsyl, and Genomic Health. He currently serves as faculty in Breast Medical Oncology at Stanford University School of Medicine and helps shape clinical strategies that integrate molecular diagnostics into oncology practice. He serves on scientific advisory boards guiding diagnostic development and implementation.
Athea Oncology; Counsyl; Droplet Biosciences; FMI (Roche); Genomic Health; LexentBio; N-Power Medicine; Stanford University
BIO
Shirley Vu is a clinical data professional with over 10 years of biotech experience and deep expertise in clinical data management, EDC configuration and implementation, and R‑based data analysis and reporting. She has led end‑to‑end data management for Phase III trials and real‑world evidence studies, ensuring data are accurate, audit‑ready, and analysis‑ready through database lock. Shirley’s technical background includes R Shiny dashboards, automated reporting pipelines, and analysis‑ready datasets that support clinical, biostatistics, and executive decision‑making. She has worked in both large biopharma and early‑stage diagnostics settings and is known for improving data quality metrics and accelerating database locks.
BIO
Tony Wu is a data science and engineering leader with over 10 years of experience building clinical data platforms and analytics infrastructure in oncology diagnostics and large enterprise environments. He has led analytics and data engineering teams, modernized cloud‑based pipelines, and delivered governed datasets that support clinical operations and biometrics. Tony builds data products that integrate clinical, biospecimen, laboratory, and operational systems under strong data governance and regulatory considerations. Recently, he has focused on practical adoption of generative and agentic AI in regulated workflows, helping teams identify high‑value use cases and implement controls that ensure trustworthy outputs.
With decades as healthtech operators, including executive leadership roles – we’ve built and scaled companies together at
Answers for innovators and investors
Clear, direct responses to your top questions about our expertise, process and medtech acceleration.
CONTACT OUR LEADERSHIP TEAM
Accelerate breakthroughs. Start the conversation.